JDRF Honors Type 1 Diabetes Research Leaders
New York, February 4, 2020—JDRF, the leading global organization funding type 1 diabetes (T1D) research, today announced the winners of five prestigious research awards: the George Eisenbarth Award for...
View ArticlevTv Therapeutics Announces Positive Results from Part 2 of the Phase 2...
HIGH POINT, N.C.–( ) February 10, 2020–vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy...
View ArticleMount Sinai Discovers New Drug Combo to Induce High Rates of Human Beta Cell...
New York, NY ( February 12, 2020)— Researchers at the Icahn School of Medicine at Mount Sinai have discovered a novel combination of two classes of drugs that, together, cause the highest rate of...
View ArticleJDRF Reaches New Milestones in Work to Drive Cures for Type 1 Diabetes and...
Annual Report showcases year of advances, driven by $121.5 million in direct support and nearly $300 million in additional funding for T1D research.read more
View ArticleStatement from Aaron J. Kowalski, Ph.D., President and CEO of JDRF, on New...
NEW YORK, February 18, 2020 – JDRF, the leading global organization funding type 1 diabetes (T1D) research, issued this statement based on two new reports issued by the Centers for Disease Control and...
View ArticleJDRF Names New Board Chair, Vice Chair
NEW YORK, February 20, 2020 – JDRF, a global leader in type 1 diabetes (T1D) research, today announced the appointment of two long-time volunteers to lead its International Board of Directors (IBOD)....
View ArticleCongressional Relief Package Extends Special Diabetes Program and Provides...
Funding for community health centers and extended prescription drug refills among the benefits for people with type 1 diabetes.read more
View ArticleZucara Therapeutics Announces US$21 Million Series A Financing
Toronto, Canada, March 31, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose...
View ArticleJDRF Statement on Lilly $35 Co-pay Card for Insulin in Response to COVID-19...
At JDRF, we welcome Lilly’s decision to introduce a co-pay card that allows anyone using commercial insurance, as well as those without any insurance, to purchase their monthly prescription of Lilly...
View ArticleJDRF Partners with Ragnar to Launch Virtual Events Supporting the T1D Community
NEW YORK, [April 15, 2020] – JDRF, the global leader in type 1 diabetes (T1D) research, today announced it will be the official charity partner of Ragnar, the largest running relay series in the world,...
View ArticleThe JDRF Beyond Type 1 Alliance Releases Recommendations for People with...
The recommendations are supported by 50 international organizations working together to curb the spread of COVID-19 and protect those most vulnerable. read more
View ArticleStem Cell Initiative Submits Signatures to Qualify for November Ballot
Overcoming Challenges from COVID-19, the Campaign Activated Patient Advocacy Groups to Collect Signatures by Mail to Cross the Finish Line While Voters ‘Sheltered in Place’read more
View ArticleInsulins Available at U.S. Pharmacies are Consistent with Product Labeling,...
The study examined the potency and consistency of active insulin in products available across the United States.read more
View ArticleJDRF Statement on NHS Englands COVID-19 Study
The study, which examines patients within the U.K. hospital system, showed an increased risk of fatality in individuals with T1D hospitalized with the coronavirus compared to type 2 diabetes and the...
View ArticleNew Research from the Indiana Biosciences Research Institute Identifies Two...
JDRF sponsors research that finds interferon-α promotes rapid changes in chromatin, triggering autoimmunity and type 1 diabetes.read more
View ArticleJDRF and Ragnar Announce the 200 for T1D Virtual Relay Challenge
New York, June 9, 2020 – JDRF, the global leader in type 1 diabetes (T1D) research, and Ragnar, the largest overnight running relay series in the United States, announced the “200 for T1D” Virtual...
View ArticleNew Findings from Groundbreaking Study Shows Extended Delay in Onset of Type...
NEW YORK – June 15, 2020— Emily Sims, M.D. today shared new findings that a breakthrough drug significantly delays the onset of type 1 diabetes (T1D).read more
View ArticleGame Over, T1D! Type 1 Diabetes Nonprofit JDRF Kicks Off Virtual Fundraising...
NEW YORK – June 26, 2020 – JDRF, the leading global organization funding type 1 diabetes (T1D) research, will hold a 12-hour charity fundraiser on Twitch this Saturday, June 27 th to bring together...
View ArticleJDRF Celebrates UnitedHealthcares Expanded Insulin Pump Coverage
In a victory for JDRF’s Coverage2Control Campaign , people with T1D now will have more choice in how they manage their diabetes read more
View ArticleJDRF & Lokai Enter Second Year Of Partnership To Continue Bringing Balance To...
The Diabetes Lokai bracelet provides wearers with a daily reminder to find balance through life’s highs and lows. read more
View Article